<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02843659</url>
  </required_header>
  <id_info>
    <org_study_id>IM128-035</org_study_id>
    <secondary_id>2016-000101-37</secondary_id>
    <nct_id>NCT02843659</nct_id>
  </id_info>
  <brief_title>Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome</brief_title>
  <official_title>A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of treatment with either
      lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren's
      syndrome as measured by the change from baseline in ESSDAI at Week 12 between active
      treatment arms (lulizumab or BMS-986142, respectively) and the placebo arm.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to meet protocol objectives
  </why_stopped>
  <start_date type="Actual">October 18, 2016</start_date>
  <completion_date type="Actual">July 24, 2017</completion_date>
  <primary_completion_date type="Actual">July 24, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in EULAR SS Disease Activity Index (ESSDAI) score at Week 12</measure>
    <time_frame>From Day 1 and Week 12</time_frame>
    <description>Changes will be compared between active treatment arms (lulizumab or BMS-986142, respectively) and the placebo arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EULAR SS Patient-Related Index (ESSPRI) score at Week 12</measure>
    <time_frame>From Day 1 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with ≥ 3 points of improvement from baseline in ESSDAI at Week 12</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with ≥ 1 point of improvement from baseline in ESSPRI at Week 12</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with both ≥ 3 points improvement in ESSDAI and ≥ 1 point improvement in ESSPRI from baseline at Week 12</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ESSDAI scores at Week 4 and Week 8</measure>
    <time_frame>Up to 8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ESSPRI scores at Week 4 and Week 8</measure>
    <time_frame>Up to 8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ESSPRI individual component dryness score at Weeks 4, 8, and 12</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ESSPRI individual component fatigue score at Weeks 4, 8, and 12</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ESSPRI individual component pain score at Weeks 4, 8, and 12</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in unstimulated salivary flow rate at Weeks 4, 8, and 12</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in stimulated salivary flow rate at Weeks 4, 8, and 12</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ocular surface staining test at Weeks 4, 8, and 12</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Schirmer's test at Weeks 4, 8, and 12</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the tear break-up time test at Weeks 4, 8, and 12</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all Adverse Events (AEs), Serious Adverse Events (SAEs), and any pre-established Events of Special Interest for lulizumab</measure>
    <time_frame>Up to 18 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant abnormalities in general laboratory tests for lulizumab</measure>
    <time_frame>Up to 18 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant ECG abnormalities for lulizumab</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant abnormalities in vital signs for lulizumab</measure>
    <time_frame>Up to 18 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all Adverse Events (AEs), Serious Adverse Events (SAEs), and any pre-established Events of Special Interest for BMS-986142</measure>
    <time_frame>Up to 18 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant abnormalities in general laboratory tests for BMS-986142</measure>
    <time_frame>Up to 18 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant ECG abnormalities for BMS-986142</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant abnormalities in vital signs for BMS-986142</measure>
    <time_frame>Up to 18 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric rating scale (NRS) for mouth dryness</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric rating scale (NRS) for eye dryness</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric rating scale (NRS) for vaginal dryness</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Global Assessment of Disease activity</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment of Disease activity</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36 acute (SF-36 acute)</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index (FSFI)</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Participation and Activity Impairment Questionnaire (WPAI)</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes Measurement Information System Fatigue Short Form (PROMIS Fatigue Short Form)</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentrations of lulizumab and BMS-986142 in pSS subjects</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Sjögren's Syndrome</condition>
  <arm_group>
    <arm_group_label>BMS-931699</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous weekly injection + daily oral placebo tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986142</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral tablets + subcutaneous placebo (weekly) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Weekly subcutaneous placebo injection +daily oral placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-931699</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>BMS-931699</arm_group_label>
    <other_name>lulizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986142</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>BMS-986142</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>BMS-931699</arm_group_label>
    <arm_group_label>BMS-986142</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Subjects diagnosed or classified as having moderate to severe primary Sjögren's
             Syndrome based on the 2016 ACR-EULAR Sjögren's Syndrome Classification Criteria for at
             least 16 weeks prior to screening

          -  ESSDAI ≥ 5 including disease activity (any score &gt; 0) in at least one of the following
             domains: Glandular, Articular, Hematological, Biological, Lymphadenopathy

          -  Positive anti-SS-A/Ro and/or anti-SS-B/La autoantibody

          -  Unstimulated whole saliva secretion &gt; 0.01 ml/min

          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to
             the start of study drug and must not be pregnant or breastfeeding. Male and female
             subjects must be willing to adhere to protocol-mandated highly effective contraception
             for the duration of the study and for the protocol-specified follow up period.
             Hormone-based contraceptive methods are not permitted

        Exclusion Criteria:

          -  Secondary Sjögren's syndrome or the presence of any other systemic autoimmune disease
             (eg, RA, SLE, multiple sclerosis, vasculitis)

          -  Very severe primary Sjögren's syndrome or severe complications of primary Sjögren's
             syndrome at the time of the screening visit

          -  Active systemic or latent bacterial (including tuberculosis), viral or fungal
             infection, evidence of current or chronic Hepatitis B or C infection, or HIV infection

          -  Any significant concurrent medical condition at the time of screening or baseline
             visit

          -  Use of methotrexate, cyclophosphamide, cyclosporine, tacrolimus, azathioprine,
             mycophenolate mofetil (MMF) or leflunomide within 12 weeks of screening visit

          -  Previous treatment with biologics therapies either marketed or in development within 6
             months prior to screening visit

          -  Treatment started or an unstable dose of hydroxychloroquine within 8 weeks of
             screening visit

          -  Oral corticosteroids &gt; 10 mg/day within 14 days of dosing (Day 1), corticosteroid
             therapy ≥ 1 mg/kg during the 4 weeks preceding enrollment, or intravenous,
             intramuscular or intra-articular corticosteroids within 4 weeks of screening visit

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Joseph Heritage Healthcare</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Georgia Rheumatology Group</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis And Osteoporosis Associates, Pa</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Clinical Research &amp; Osteoporosis Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pmg Research Of Wilmington Llc</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paramount Medical Research &amp; Consulting, Llc</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center For Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635-8406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acme Research, Llc</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Tennessee Research Institute</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santiago De Chile</city>
        <state>Metropolitana</state>
        <zip>7501126</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito Fededral</state>
        <zip>11850</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>97070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Veracruz</city>
        <zip>91910</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cercado De Lima</city>
        <state>Lima</state>
        <zip>1</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 31</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto De Ginecologia Y Reproduccion Inv. Clinical Sac</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 33</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Reumatologii i Chorob Wewnetrznych</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>121374</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stellenbosch</city>
        <state>Western Cape</state>
        <zip>7600</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Hungary</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2016</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

